Challenges and opportunities for non-antibody scaffold drugs. Issue 10 (October 2015)

• Record Type: Journal Article
• Authors: Vazquez-Lombardi, Rodrigo; Phan, Tri Giang; Zimmermann, Carsten; Lowe, David; Jermutus, Lutz; Christ, Daniel
• Is Part Of: Drug discovery today. Volume 20:Issue 10(2015)
• Page Start: 1271
• Page End: 1283
• Publication Date: 2015-10
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2015.09.004
• Languages: English
• ISSNs: 1359-6446

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Non-antibody scaffold drugs are a promising new class of biologics drugs.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">The first candidate scaffolds are now moving into clinical development and practice.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Challenges remain and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.</p> </list-item> </list> </p> </sec> </abstract>